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Abstract  
This study presents industry perspectives on the challenges related to market access of innovative drugs in general 
and oncology drugs in specific. Fifteen interviews were conducted with representatives of pharmaceutical 
companies and industry associations. Interviewees call for a broader recognition of value within the assessment 
and appraisal of drugs. According to interviewees, focus on value is jeopardized by the lack of a common value 
definition across Europe, poor availability and validity of value measures and cost-saving measures such as 
external reference price setting and cost-effectiveness analysis at the side of the payers. Centralized assessment of 
relative-effectiveness at European level would provide a common value estimate across member states, 
independent of financial drivers. Empirical evidence on patient reported outcomes and societal preferences is 
however essential in the development of a value definition. Furthermore, value-based pricing would imply a 
dynamic approach where the price is differentiated across indications and across the lifecycle of the drug, 
especially in fields such as oncology. Financial drivers however also threat the application of value-based pricing 
at the side of the industry, making value-based profitability a more appropriate term. 
Key points  
- Representatives of the pharmaceutical industry call for a broader recognition within the assessment and 
appraisal of innovative drugs  
- Focus on value within the assessment and appraisal of drugs is jeopardized by financial drives as the side 
of industry and at the side of the payers 
- A well-considered value-framework, with attention for patient reported outcomes, societal preferences 
and dynamic approach on the drug life cycle,  needs to be incorporated in assessment and appraisal  at 
national and European level in order to coordinate the views of different stakeholders and allow efficient 
resource allocation  
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Introduction 
In the aftermath of the economic crisis of 2010, public spending to health care is recovering slightly in line with 
the economic growth since 2013 [1]. Spending to pharmaceuticals was cut by the introduction of cost containment 
measures in many countries and the end of the patents for some blockbuster drugs [1]. In times of budgetary 
constraints, health authorities and payers still keep struggling with new innovations that offer in their view too 
limited benefits at an unjustified high price. This is even more important for disease areas as oncology, in which 
high unmet needs remain. With more than 3 million new cases and 1.7 million deaths each year, cancer remains 
the second most important cause of death and morbidity in Europe [2]. The oncology market is typically expanding 
by high cost drugs that offer relatively limited benefits in terms of overall survival (OS) or progression free survival 
(PFS) [3]. Ipilimumab is one of the numerous examples of drugs that has recently been highly criticized as an 
overexpensive drug since it was launched in UK at a price of £75,000 for a four dose treatment course, yielding 
3.7 months in median overall survival in the phase 3 trial [4]. Pharmaceutical companies are put under pressure 
and blamed for setting unsustainably high prices that threaten the accessibility of health care for patients [5]. While 
an upward trend in both the launch price of oncology drugs as well as the price per unit of health gain indeed raises 
questions about the future sustainability and accessibility of public health care systems [3,6], a decline in economic 
return for pharmaceutical companies possibly threatens future innovation [7]. The current pipeline is however 
well-filled with oncology agents, promising evolutions towards individualized therapies, immuno-oncology and 
combination treatment schemes and thus predicting more hurdles to overcome [8].  
Marketing authorization is currently centralized at European level for most drugs, including oncology drugs, and 
involves a first step in assessment of the drugs’ safety, quality and efficacy irrespective of financial consequences 
or relative benefit compared to alternatives. Drug appraisal, comprising the value of the drug in relation to its 
competitors, is exclusively performed at the national level of the member states in the context of price setting and 
reimbursement decisions. Previous research already showed a variety of instruments for price setting and 
reimbursement of oncology drugs across European member states, leading to heterogeneity across and within 
countries, and poor transparency towards all stakeholders involved [9,10]. Efficient allocation of the scarce 
resources and sustainable development and access to innovative drugs can only be obtained when stakeholders 
coordinate their individual views as much as possible. The aim of this study is to reveal the perspective of the 
pharmaceutical industry on development and market access of innovative drugs in general and oncology drugs in 
particular, and discuss their proposals for future improvement.  
 
Methods 
Semi-structured interviews were conducted with representatives of the pharmaceutical industry between August 
and November 2015. Interviewees were invited through e-mail and telephone based on purposive sampling. 
Companies with oncology drugs in their current or past product portfolio were selected. Additionally, two industry 
associations were included. Interviewees affiliated to these companies or associations were selected based on their 
knowledge and experience related to market access strategies, including marketing authorization, price setting and 
reimbursement of (oncology) drugs. After searching the literature for evidence about industry perspectives on 
market access of drugs in general, an interview guideline was designed by selecting eight relevant statements from 
the literature (table 1). The statements were discussed with the interviewees during face-to-face interviews or by 
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telephone, dependent on their availability and preferences. Notes were taken during the interview and in case of 
permission of the interviewee, the interview was audio-recorded and ad verbatim transcribed. The grounded theory  
approach was applied to analyze the interviews using the qualitative data analysis software package Nvivo®. All 
transcripts were anonymized. Interviews were repeated until data saturation. All interviewees received the results 
section for final approval, while the remaining manuscript was written independently 
 
Results 
Fifteen interviews were conducted, involving thirteen pharmaceutical companies and two pharmaceutical industry 
association. Two of the fifteen interviews were conducted by telephone instead of face-to-face. Fourteen of the 
fifteen interviews were audio recorded.  
Research and development 
It was previously suggested in literature that companies sometimes focus on research hypothesis instead of unmet 
medical or social needs [11]. Interviewees show divergent opinions on the role of medical and social need in the 
orientation of research and development of innovative drugs. While some interviewees agree that social or medical 
Tabel 1: Statements from the literature for semi-structured interview guideline  
 “Manufacturers sometimes set research priorities on the basis of the pursuit of a research hypothesis, as 
opposed to developing new technologies that meet unmet social need.”   (11) 
“Resources for development of new technologies can be used much more effectively if industry and HTA 
agencies were to collaborate at an early stage in the development process.” (28) 
“The main actors in the health care sector have different perspectives on the value added by health 
technologies.” (11) 
“Manufacturers feel that the restrictions on the use and price of health technologies resulting from HTAs 
limits their sales potential and ultimately the profits from which future research has to be funded.” (11)  
“It has been discussed if the QALY fully captures the benefits of new cancer drugs. The higher cost per 
QALY criteria for oncology drugs may reflect a view that there may be an additional benefit or value of 
treatment that should be considered.” (29) 
 “The question how to define justifiable prices for oncology drugs needs to be addressed. Currently, prices 
are often set in relation to international standards and investments of manufacturers.” (30)  
“Value based pricing is likely to give manufacturers an incentive to more closely align their R&D with 
social objectives” (30)   
“If all elements of value are considered and taken into account in decision making, there is a risk that 
higher prices will be the result.” (30)  
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need has no impact or only becomes important at a later stage of development, others indicate that social and 
medical need is increasingly driving drug development. 
“Patients are put in the first place, second we have to create trust amongst our payers, amongst our patients and 
physicians, and then, in the end the business will follow and the money will come…we have a commercial 
organization and in the end it is about revenues, that is correct, but we put patients in the first place.” (I1) 
For some interviewees it is not completely clear what the health authorities’ needs and priorities are.  
“We have no clear guidance on the unmet needs that needs to be worked upon. Where are the priorities? They 
have not been put forward. So how can we address those unmet needs if we don’t know what they are for the 
authorities?” (I2)  
According to other interviewees, needs are perceived in function of willingness to pay related to pricing and 
reimbursement.  
 “A drug that does not bring added value will have lot of difficulties to get reimbursed. Today, there are already 
a lot of incentives to orient investment and research in function of a need.” (I3) 
“I don’t think that we would develop a technology that meets a need if nobody is going to pay for that need. 
Because there is no market, no opportunity for companies” (I4) 
Some interviewees do not believe that willingness to pay can steer research and development into a certain 
direction.  
“It would be possible to indicate the areas where there is a need, where it would be interesting to do research…but 
I don’t believe that you can guide research…you need companies that do their research, they can come with a 
proposal, and then the society has the right to say it is not relevant enough, we don’t pay for it.” (I5) 
Marketing authorization  
Currently, national legislation and practice in European member states concerning price setting and reimbursement 
of drugs leads to a heterogeneity across Europe. Interviewees are in favor of a centralized assessment of the relative 
benefit at European level within the process of marketing authorization. This would make the focus for companies 
more clear as it can provide a common basis for assessment and appraisal of drugs across European Member states. 
“The assessment of relative efficacy and effectiveness based on solid science presents a set of core similarities 
across countries. It is therefore reasonable that greater collaboration would enhance efficiency and predictability 
for all stakeholders involved.” (I6)  
Price setting 
Interviewees however hold the opinion that as long as the economic system is different for each country, the 
appraisal of pharmaceuticals needs to remain a national responsibility and price must depend on the national budget 
and priorities. 
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“I don’t believe that price setting in Europe needs to be homogenous....you need to differentiate across countries…. 
But currently it is transforming towards a national competence that is more embedded in Europe, and this is a 
good thing.” (I5) 
Interviewees emphasize that prices should however not just allow to cover costs made in the past but more 
importantly, needs to ensure investments in the future pipeline.  
“First of all, you want to make a difference, second, you want to make money. Not just because you love to earn 
money, but because you would like to keep things going. We want to develop, we want to innovate. Of course you 
need to please shareholders and draw dividends and make profits but most important, you want to keep going the 
R&D.” (I7)  
Companies further fear they cannot meet the expectation of the payers. According to the interviewees, payers only 
show willingness to pay for breakthrough innovation, while interviewees are convinced that a step by step approach 
will lead to tremendous benefits at the long-term.  
“I mean if companies would be able to just produce what payers are expecting, and just breakthrough…I think 
they would do it. If they don’t, it is just because it doesn’t work that way.” (I4) 
It is indicated by interviewees that the focus on medical needs provokes a shift from pharmaceuticals for primary 
care to specialized medicines where the volume of sales is lower and therefore price needs to be higher to recoup 
the costs.  
“The more specific you go, the less patients there are and therefore, the cost should sometimes be higher to recoup 
the investments.” (I8) 
A number of countries currently applies external reference pricing (ERP) in order to set prices based on the price 
in a basket of other countries. This can lead towards harmonization of price levels. Furthermore, a price decrease 
in one particular country can have a tremendous effect on price levels in the basket of reference countries, and 
interviewees confirm that this can motivate pharmaceutical companies to keep list prices high.  
“Also you have countries who use ERP, who create a system where prices are kept as high as possible by 
companies. I think that is an aspect of the situation that explains why oncology drug prices are kept as high as 
possible, and cannot be defined in just one way, or justified in just one way.” (I9) 
It was emphasized that the inherent value of the drug is neglected within the system of ERP. 
“The problem that we see today is that a lot of countries have this health technology assessment (HTA), but at the 
same time there is this ERP. What is the aim of having these data or having this discussion around which premium 
is appropriate when in the end you say I am not willing to pay more than my neighbor?” (I4)  
Also taking into account cost-structure within price setting will not provide the right incentives according to the 
industry. 
“Think in terms of incentives. If they pay your R&D costs, they say it doesn’t matter what you develop, they will 
pay it anyway. The only right incentive is to pay a fair price for products they need, and that is value-based pricing. 
The government needs to say develop value and we will pay for it.” (I7) 
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Clinical value 
Companies value a drug based on the clinical, economic and societal value. Interviewees indicate that the full 
value of the product is currently not sufficiently captured during the assessment and appraisal of drugs. At the 
clinical level, interviewees doubt whether OS and PFS cover the long-term benefits of treatments based on new 
mechanisms of action such as present in immuno-oncology. 
 “The clinical benefit scale today captures clinical value. We look at the curve of PFS or OS, and basically we 
know that until five years value can be captured in clinical trial setting, but what can’t be captured is the area 
after the curve that looks at the longer quality of survival. And this is not captured everywhere, and I suppose it is 
normal because these things that are coming to the market are new. There is work to be done to develop value 
mechanisms beyond the clinical trial setting, tools that allow to capture broader value. And really today what is 
being used is the median OS, or PFS. We think that this should be broader to really capture what is the benefit.” 
(I10) 
Further, it is questioned by interviewees whether OS, PFS and quality of life cover most relevant outcomes 
according to patients and physicians.  
“The focus is recently very much on OS and quality of life but…I think there are other things that can define the 
value of the drug. How many patients can you treat with your drug? Is it a drug with a different mode of action?  
What can this bring to the patient and the physician?  Is it interesting to have one more drug, without necessarily 
prolonging survival? Is it good to have one extra therapeutic option? “(I9) 
Interviewees call for standardized, validated and recognized measures for patient reported outcomes (PRO).  
“How do you measure quality of life or PRO in a way that gives you data that are recognized as valid?… There 
is no guidance or commonly agreed framework on how we should do it.” (I10) 
Societal value 
At the economic and societal level, interviewees feel that the broader economic and societal value of a product, 
resulting from savings at the long term, such as recessed hospitalizations and absence from work, is often ignored 
by decision makers. 
“Very often many countries don’t include societal perspectives. So what about the treatment costs after cure? Very 
often you have to model or calculate costs during the disease period, but if you cure, the patients survives, what 
about the additional costs or savings after surviving?” (I11) 
Cost-benefit analysis 
Cost-effectiveness analysis is introduced in a large number of European countries in order to evaluate the cost-
benefit ratio of a drug in terms of an incremental cost-effectiveness ratio (ICER), expressed as cost per quality 
adjusted life year (QALY). This was recognized by interviewees as an appropriate tool to compare the costs and 
benefits of different treatments with each other but several remarks on the system where provided. Several 
interviewees argued that considering an ICER within price setting and reimbursement evaluations does not provide 
appropriate incentives to the pharmaceutical industry. According to the interviewees, the ICER motivates to 
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develop in an area where existing treatments are expensive, because you can add up the price of the new technology 
to the existing price, resulting in a lower ICER compared to the situation where there is no (expensive) alternative 
treatment. Due to methodological requirements, costs per QALY will always be too high in domains where 
effectiveness is low and patient populations are small. 
“In the field of unmet needs, you will be punished by the QALY system because you have no cost-reference. By 
considering cost per QALY, they say do not develop in an area where prices are low, do not develop in an area 
where there are no big gains in effectiveness expected and do not in an area where patient populations are small.” 
(I7) 
Furthermore, disease specific outcome that are of high relevance for the patient are often not captured in QALY 
measures as these are mainly based on health outcomes measured with EQ5D, a standardized, 5 dimension scale 
developed by Euroqol. 
“EQ5D does not capture everything, like hair loss is not captured, so hair loss has no influence on the QALY.  
Which is crazy because I can imagine that hair loss would have an impact on quality of life.” (I3) 
Implications for oncology drugs  
Interviewees urge on a broader consideration of value through the lifecycle of the product especially when drugs 
are initially only used in late stage diseases, such as is often the case for oncology drugs. This is due to ethical 
considerations, where one tries to address the highest need and minimize potential risks for patients. This makes 
it hard to prove value in the initial stage of drug assessment and appraisal.  Benefits will anyhow be larger at a 
later stage of market access when the indication has broadened.  
“Once an oncology medicine is more established, it can be used in an adjuvant curative setting, as in patients with 
better prognosis, before tumors have spread. Measured outcome, by definition for such patients are often better 
than patients whose cancer is more advanced. Often, prices that were too high at initial assessment, can turn out 
cost-effective by the time the medicine is in an adjuvant or broader use.” (I6) 
Additionally, recognition of value can mean restriction of the drug towards the most valuable indication.  
“Personally I believe you should use the drugs where they are most appropriate. You should use them where they 
deliver the highest value. Where they deliver the highest value you can justify better your price than when they are 
used in an inappropriate way.” (I12) 
Alternatively, if payers recognize value and are willing to apply value-based pricing, they would be ready to apply 
indication specific pricing, as the value for oncology products can definitely differ between indications.  
“Now we have average prices per milligram. And you can have a drug in breast cancer, colorectal cancer and 
adjuvant breast cancer and today this drug has the same price per milligram in all these indications. If we are in 
a society that is willing to pay for value, then the pricing model should allow for different prices per indication, 
as the value of the drug might be very different. This could make the discussion more acceptable for all 
stakeholders.“ (I3)  
Belgium 
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Several issues related to the Belgian system for price setting and reimbursement of drugs were mentioned based 
on the experience of the interviewees with relation to price setting and reimbursement files concluded in Belgium 
in the past. In the Belgian law, therapeutic value is defined in function of efficacy, effectiveness, safety, 
applicability and convenience for use. Therapeutic value is considered following the application for 
reimbursement, together with the price of the drug, the therapeutic and social need, and budget impact and cost-
benefit ratio [12].  Interviewees are favorable to the law, but are critical of the application in practice. They have 
the impression that at the Belgian level, budgetary control currently overrules value assessment.  
“I think the law goes very broad and specifies the five criteria that they use to define the added value of a drug. 
But in the end you always see that it boils down to the cost of your drug compared to the cost of the other ones. 
Adding quality of life, adding efficacy, adding a better safety for your drugs, and especially quality of life and 
safety aspects… usually they are not valued that high by the authorities.” (I1) 
Cost-effectiveness analysis is mandatory for drug that claim added therapeutic value. Some interviewees perceive 
it only as an entry ticket to the procedure which is not further taken into account in the evaluation for 
reimbursement, since budget impact takes the lead. Other interviewees mention that even when your budget impact 
is relatively low, the ICER will be put forward as an issue.  
“If you are not cost-effective you don’t get reimbursement, but if you are cost-effective, the budget can be too high. 
Cost per QALY must be zero in Belgium before you can get reimbursement.” (I1)  
Interviewees call for a better recognition of the patient perspective. In the current system, health insurance funds 
have the task to represent the patients, but at the same time they are responsible for the public health budget, which 
results in a dual role with inherent conflicts. This further strengthens budget impact as a deciding factor for 
reimbursement. 
“Health insurance funds took the responsibility to defend the patient. They probably did that in good faith, but 
know they are payer as well as patient representative. That is a dual role, which is not easy” (I5)  
Companies show incomprehension toward the Belgian practice in which reimbursement for an additional 
indication is coupled with a price decrease. When an additional indication is approved for a drug that was already 
reimbursed, the company needs to compensate one third of the additional budget impact related to the new 
indication. This gives the impression towards the companies that the added value of this new indication is not 
taken into account.  
“The rule in Belgium in very special. When you can show the budget impact with the new indication compared to 
budget impact that was existing without a new indication, one third of the increase in the budget should be taken 
by the company, meaning that you have to decrease the price of the product by X percent. … But maybe you can 
show really a therapeutic added value for the new indication, this will not be taken into account.” (I13) 
Interviewees indicate that there is no fixed period of exclusivity anymore where companies can recoup their costs 
and this introduces new financial uncertainties to the companies. Companies will anticipate on price pressure and 
price erosions, leading to higher prices at initial price setting.   
Discussion  
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This study presents industry perspectives on the challenges related to market access of innovative drugs in general 
and oncology drugs in specific. Industry calls for a broader recognition of value within the assessment and 
appraisal of drugs. Pricing in function of value has the potential to stimulate valuable innovation since industry is 
eager to orient research and development of drugs in function of willingness to pay. The lack of a common value 
definition across European member states, poor availability and validity of value measures, as well as financial 
responsibilities at the side of both industry and payer, however threat the application of value-based pricing.  
The pharmaceutical landscape is currently changing. While in the early 90’s massive entities were set up to profit 
from the economies of scale, companies currently focus on one particular area of strength [13]. This goes along 
with a move from drugs for primary care towards specialty drugs and biologicals for unmet needs [13]. While 
some companies hold on the principle of a supply driven market where payers need to deal with what industry 
brings on, a transition towards a demand driven market was observed in this study. Companies show willingness 
to orient their investments to areas of unmet needs, on the condition that the priorities are clearly defined and 
benefits in areas of unmet need will be rewarded. Companies have to tailor drug applications to the individual 
market requirements in European member states, evoking frustrations at the side of the company when objective 
measures, even those assessed at European level such as efficiency and side effects, are not treated the same way 
across member states. In the first step of drug assessment, regulators however only focus on the balance between 
benefits and risks to grant marketing authorization. Clinical superiority was only defined at European level in the 
context of EU orphan drug legislation in 2000.  In 2008, the High Level Pharmaceutical Forum of the European 
Commission published core principles on clinical superiority including a definition on relative efficacy (RE) [14]. 
First pilot projects of The European Network for Health Technology Assessment (EUnetHTA), established in 2009 
in order to work towards more effective use of resources in the HTA process,  strived for a common HTA 
assessment report across European member states, presenting the core HTA information [15]. An assessment of 
the external validity of national assessments of RE however resulted in a pessimistic view on potential 
harmonization [15]. Although there appears to be a commonality between the use of RE at national level, the way 
that study design, outcomes and comparators were evaluated and accepted differs [15]. Early dialogue can aid 
understanding of possible differences and will allow companies to consider the product development fit for 
regulatory purposes. Therefore, the SEED (Shaping Early Dialogue) consortium was set up in 2014 under 
supervision of Haute Autorité de Santé (HAS) in order to include 14 partners within 10 early dialogues between 
2014 and 2015. Centralized assessment of RE is clearly not likely to be quickly achieved, but there is a growing 
belief from industry as well as regulators that EU assessment of RE can strength the EU market and is expected to 
trigger allocation of research and development resources away from me-too drugs towards drug development 
programs that aim superiority claims [14,16]. Centralized assessment of RE based on transparent grounds can 
enable focused clinical trial design with generation of relevant data [16]. Costs will be lower and quality will be 
improved at the benefit of both industry and public health systems, on the condition that the assessment of RE is 
recognized and shared across MS. Standards for clinical trials will therefore raise when evidence needs to be 
reliable and applicable to all MS. While industry believes a centralized assessment of RE can harmonize and 
strengthen value consideration within the assessment by national health authorities, some authors doubt whether 
this would lead to enhanced access to cancer medicines as drug appraisal, related to health care costs, remains to 
be managed at national or local level [16].  
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At the side of the payers it is debated whether prices of drugs are still proportionally related to their benefits [6,8]. 
At the same time, pharmaceutical companies doubt whether current assessment and appraisal procedures capture 
the full value of drugs. Administrative pricing procedures such as ERP anyhow neglect the intrinsic value of the 
drug and although the number of countries that solely relies on this pricing method is limited, the influence on 
industry strategies and consequently medicine prices needs to be emphasized [17,18]. ERP, together with the fact 
that parallel trade is allowed within the EU single market, can urge companies to artificially keep up the list price, 
which does not reflect confidential discounts and rebates. In countries such as Belgium, this can exemplify 
conflicting interest when the main focus of payers is on the budget, while the Belgian list price is used as a reference 
in a large number of other countries applying ERP. Industry perspectives indicate that the Belgian policy and 
practice fosters price setting away from the inherent drug value, as companies intend to anticipate on price erosions, 
budgetary pressures and an impact on the price in other countries due to ERP. A comparison between value-based 
pricing and EPR, conducted in the lap of the European Commission, was anyhow in favor of value-based pricing 
since EPR does not aim to reward (future) innovation [19]. According to the EU commissions report, development 
of valuable drugs can only be motivated when assessments and appraisal consider a societal perspective in 
determination of costs and benefits associated with a new technology [19]. Evidence about the societal worth of a 
broader benefit consideration is increasing. A study in 4118 citizens of Great Britain suggested a significant value 
for wider societal benefits [20]. Also a population study conducted in Belgium showed that the effect of 
innovations on current expenditures is valuable according to society [21]. While siloed funding is applied among 
European countries, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) is one of the sole exemptions 
where pricing and reimbursement decisions focus on value from the societal perspective instead of the health care 
perspective only [19]. According to TLV guidelines, this means that all relevant costs and revenues irrespective 
of the payee should be considered, including cost of production loss and cost of increased survival as well as 
benefits to both caregivers and patients [22]. Prices in Sweden are however among the highest in Europe and 
adoption of the societal perspective considerably increases the information requirements, so attention for 
accessibility in terms of time and price is an asset [19,23]. With regard to clinical benefits, research already 
suggested that societal valuation of quality of life is overruling the valuation of life expectancy when considering 
both the initial health state of the patients as well as treatment effects [24,25]. Several stakeholders currently call 
for a broader inclusion of patient reported outcomes (PRO), referring to multi-dimensional measures of symptoms, 
quality of life, health status, treatment adherence and treatment satisfaction. Demographic evolutions towards an 
aging population and more chronic diseases provide a context in which the relevance of outcomes related to the 
wellbeing of the patient, such as of quality of life in the broad sense is growing. By the end of 2014, a reflection 
paper discussing the use of PRO in oncology was added to the scientific guidelines for quality, safety and efficacy 
requirements prepared by the European Medicines Agency’s (EMA) Committee for Human Medical Products 
(CHMP) [26]. In this reflection paper, the benefit of capturing personal and social context of the disease and 
treatment experience in addition to objective clinical measures such as OS and PFS was set against its challenges 
in setting the degree of clinically relevant differences, difficulties in sensitivity, and problems with feasibility in 
longitudinal studies [26]. Results in lung cancer previously showed that similar outcomes where shown for PFS 
than for time to significant deterioration in tumor related responses as measured by PRO, questioning the added 
value of PRO [26]. Validated tools to measure PRO, also including Health Related Quality of Life (HRQoL) 
measures are scarce. Weighting systems to link disease specific quality of life outcomes to utility scores are even 
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lacking; challenging their use in cost-effectiveness analysis. Generic health classification systems such as EQ5D 
remain the single valid tool for QALY weighting, often based on population preferences since also at this level 
disease specific patient preferences are lacking.  
Pricing in terms of clinical-effectiveness as well as cost-effectiveness, sets the costs and benefits of a new treatment 
against those of the existing alternatives and it was argued by Howard et al. that setting prices of new drugs based 
on prices of existing therapies is also against intrinsic value consideration, consistent with models for reference 
pricing [6]. The benefit of the new drug can add up to the price of existing treatments, providing incentives for 
development in areas of highly priced existing therapies. Cost-effectiveness analysis in oncology is anyhow to the 
prejudice of industry since it is often applied immediately after launch, considering advanced or palliative stages 
of the disease. The End-of-Life guidance was introduced in UK to adjust the cost-effectiveness threshold for late 
stage treatments.  Although society attaches higher value to treatments for more severe disease, treatments for 
palliative diseases as such, are not valued higher than treatments for early stages of diseases [20]. In the 
Netherlands, the thresholds are applied in a flexible way, adjusting these to severity of disease [10]. The evolutions 
in drugs development are however likely to further threaten the applicability of cost-effectiveness analysis as the 
relevance is somewhat questioned within small patient populations and combination therapies. Because the price 
per milligram is fixed across indications while value can differ, the actual cost-effectiveness also varies across 
indications. Oncology drugs are characterized by multiple indications with more than 50% of major cancer 
medicines marketed in 2014 were for multiple indications [8,27]. Setting a price based on the indication shortly 
after launch can influence patient access during the life cycle of the drug. If the single price is based on higher 
value indications, the price might be higher than what is optimal for subsequent indications, leading to restricted 
access [27]. If the price is initially set for lower valued indications, which will often be the case for oncology drugs, 
this might discourage companies to further develop valuable indications [27]. As value changes over the life cycle 
of a drug, value-based pricing challenges a dynamic life cycle approach where price discrimination across 
indications is allowed. Managed entry agreements allow to set confidential contributions based on performance of 
the drug, even beyond clinical trial setting, promising a leading role for managed entry agreements for oncology 
drugs in the future. It is however doubted that industry is ready to set the price fully in relation to value as this will 
not lead to sufficient return in particular situations such as small indications, making value based profitability a 
more appropriate concept than value based pricing. Furthermore, besides a considerable responsibility in 
sustaining the provision of and access to innovative drugs, the financial responsibilities of health authorities 
towards the budget cannot be neglected. It remains tricky how to define value and link value with an acceptable 
price level for all stakeholders, involving an acceptable profitability towards the industry and reasonable budgetary 
impact towards the health authorities.  
This study suffers of three main limitations. First, despite the fact that interviews were repeated until data 
saturation, a variety of opinions was observed across interviewees. The results of this study aim to reflect these 
differing opinions. Second, the experience of some of the interviewees was limited to the Belgian situation, while 
the results are applied to the European situation in general. Third, the experience of majority of the interviews 
refers to innovative drugs in general and not solely to oncology drugs, therefore results specific for oncology drugs 
are described separately.  
Conclusion 
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Value consideration is key, especially in expanding areas that face expensive therapies such as oncology. On the 
one hand value consideration can help to define priorities, pursue and reward development of valuable drugs at 
the benefit of industry. On the other hand, a clear value definition can help to discriminate between therapies that 
offer marginal or substantial benefits at the side of the benefit of the payer. Focus on value is however jeopardized 
by financial drivers both at the side of the industry (return) and payers (budget). Centralized assessment of RE can 
provide a common value estimate across member states, independent of financial drivers. Given current 
demographic and scientific evolutions, re-consideration of the concept of value is however required and empirical 
evidence suggests that developments of validated measures for PRO and societal benefits are appropriate. At the 
level of the member states, payers needs to take account of contradictory incentives for industry that some cost-
saving measures such as ERP and cost-effectiveness analysis can evoke.  
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